News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics
PORTLAND, Ore.--(BUSINESS WIRE)--May 24, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that it has received a Notice of Allowance for U.S. Patent No. 7,049,431 titled "Antisense Antibacterial Cell Division Composition and Method." The patent describes the use of NEUGENE (R) antisense
View HTML
Toggle Summary AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference
PORTLAND, Ore.--(BUSINESS WIRE)--May 11, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Monday, May 15, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the Rodman & Renshaw 3rd Annual Global Healthcare Conference,
View HTML
Toggle Summary AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
PORTLAND, Ore.--(BUSINESS WIRE)--May 10, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) will present initial data from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection at the prestigious International Conference on Antiviral Research (ICAR) annual
View HTML
Toggle Summary AVI BioPharma Incorporated First Quarter 2006 Financial Results Conference Call Transcript
Moderator: Jody Cain May 5, 2006, 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2006 First Quarter Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we’ll hold a Q&A session.
View HTML
Toggle Summary AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza
NeuGene Antisense Efficacy Against Influenza Strains Reported at the International Conference on Antiviral Research   PORTLAND, Ore.--(BUSINESS WIRE)--May 9, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented positive preclinical data, resulting from preclinical experiments targeting
View HTML
Toggle Summary AVI BioPharma Announces First Quarter Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--May 5, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three months ended March 31, 2006. For the first quarter of 2006, AVI reported a net loss of $9.1 million, or $0.18 per share, compared with a net loss of $5.5 million, or $0.13
View HTML
Toggle Summary AVI BioPharma Announces 2006 First Quarter Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--April 28, 2006--AVI BioPharma Inc. (Nasdaq:AVII) today announced that the company will hold a conference call to discuss its 2006 first quarter financial results on Friday, May 5, 2006, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
View HTML
Toggle Summary AVI BioPharma to Present at UBS Global Specialty Pharmaceuticals Conference
PORTLAND, Ore., Apr 21, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Monday, April 24, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Specialty Pharmaceuticals Conference to be
View HTML
Toggle Summary AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
Data from the Phase I/II Accepted for Oral Platform Presentation at ICAR   PORTLAND, Ore.--(BUSINESS WIRE)--April 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today issued an update on the status of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection.
View HTML
Toggle Summary AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NEUGENE Antisense Therapeutic
PORTLAND, Ore.--(BUSINESS WIRE)--March 30, 2006-- Preclinical Results by Four Independent Laboratories Summarized and Presented at Keystone Symposia: Advances in Influenza Research AVI BioPharma, Inc. (Nasdaq:AVII), today announced the presentation of research results titled "Inhibition of Multiple
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.